We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Read MoreHide Full Article
Key Takeaways
COGT soared after its SUMMIT study met all endpoints in non-advanced systemic mastocytosis.
Bezuclastinib showed strong symptom reduction and biomarker response versus placebo.
The drug was well-tolerated, and an FDA submission is targeted for the end of 2025.
Shares of Cogent Biosciences (COGT - Free Report) soared 23.4% on Monday after the company reported positive top-line data from a late-stage study of its investigational candidate, bezuclastinib, for treating non-advanced systemic mastocytosis (SM) patients.
The registration-enabling phase III SUMMIT study achieved the primary and all key secondary endpoints, demonstrating clinically meaningful and highly statistically significant improvements upon treatment of the SM patient population with bezuclastinib, over placebo. The data readout also includes significant improvements in patient-reported symptoms and objective measures of mast cell burden.
SM is a rare hematological disease impacting the immune system with debilitating symptoms that take a serious toll on the physical and psychological quality of life of patients.
Year to date, shares of Cogent Biosciences have gained 19.9% against the industry’s 1.9% decline.
Image Source: Zacks Investment Research
COGT’s Systemic Mastocytosis Study Data in Detail
Per the data readout from Part 2 of Cogent Biosciences’ SUMMIT study, treatment with bezuclastinib showed a highly statistically significant improvement in total symptom score (TSS) at 24 weeks. TSS was measured using the Mastocytosis Symptom Severity Daily Diary. Patients in the bezuclastinib group experienced a mean TSS reduction of 24.3 points compared to a 15.4-point reduction in the placebo group. This resulted in a placebo-adjusted improvement of 8.91 points in favor of bezuclastinib.
Beyond the primary endpoint, the study also achieved highly statistically significant results across all key secondary endpoints. Notably, 87.4% of patients treated with bezuclastinib saw a ≥50% reduction in serum tryptase levels — a biomarker of mast cell activity — while no patients in the placebo group achieved this level of reduction. These results underscore the broad clinical benefit of bezuclastinib in treating symptoms and biological markers of disease.
Cogent Biosciences also reported that bezuclastinib was overall well-tolerated and demonstrated a favorable safety profile, supporting chronic use in this patient population. Most adverse events related to treatment were mild to moderate in severity.
COGT’s Next Steps in the Bezuclastinib Development Program
Based on the encouraging data readout, Cogent Biosciences is gearing up to submit its first new drug application to the FDA, seeking the approval of bezuclastinib for non-advanced SM, by the end of 2025. Subject to approval, management believes that the candidate has the potential to become a new standard of care for this patient population, where there is a significant unmet medical need.
A comprehensive analysis of the full SUMMIT Part 2 data is currently underway and COGT intends to present the detailed findings at a major medical conference later this year.
Apart from the non-advanced SM indication, Cogent Biosciences is simultaneously evaluating bezuclastinib for advanced SM and gastrointestinal stromal tumors in separate pivotal late-stage studies, APEX and PEAK, respectively. Top-line data from both phase III studies are anticipated in the second half of 2025.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.44 to 70 cents. Loss per share estimates for 2026 have narrowed from $1.45 to $1.08 during the same period. IMCR stock has gained 9.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 90 days, Verona Pharma’s bottom-line estimates for 2025 have significantly improved from a loss of 7 cents per share to earnings of 22 cents. During the same timeframe, estimates for 2026 earnings per share have improved from $2.21 to $2.88. VRNA stock has soared 96.4% so far this year.
Verona Pharma’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, delivering an average negative surprise of 6.76%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.27 for 2025 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.34 over the same timeframe. Year to date, shares of Bayer have surged 56.6%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
Key Takeaways
Shares of Cogent Biosciences (COGT - Free Report) soared 23.4% on Monday after the company reported positive top-line data from a late-stage study of its investigational candidate, bezuclastinib, for treating non-advanced systemic mastocytosis (SM) patients.
The registration-enabling phase III SUMMIT study achieved the primary and all key secondary endpoints, demonstrating clinically meaningful and highly statistically significant improvements upon treatment of the SM patient population with bezuclastinib, over placebo. The data readout also includes significant improvements in patient-reported symptoms and objective measures of mast cell burden.
SM is a rare hematological disease impacting the immune system with debilitating symptoms that take a serious toll on the physical and psychological quality of life of patients.
Year to date, shares of Cogent Biosciences have gained 19.9% against the industry’s 1.9% decline.
Image Source: Zacks Investment Research
COGT’s Systemic Mastocytosis Study Data in Detail
Per the data readout from Part 2 of Cogent Biosciences’ SUMMIT study, treatment with bezuclastinib showed a highly statistically significant improvement in total symptom score (TSS) at 24 weeks. TSS was measured using the Mastocytosis Symptom Severity Daily Diary. Patients in the bezuclastinib group experienced a mean TSS reduction of 24.3 points compared to a 15.4-point reduction in the placebo group. This resulted in a placebo-adjusted improvement of 8.91 points in favor of bezuclastinib.
Beyond the primary endpoint, the study also achieved highly statistically significant results across all key secondary endpoints. Notably, 87.4% of patients treated with bezuclastinib saw a ≥50% reduction in serum tryptase levels — a biomarker of mast cell activity — while no patients in the placebo group achieved this level of reduction. These results underscore the broad clinical benefit of bezuclastinib in treating symptoms and biological markers of disease.
Cogent Biosciences also reported that bezuclastinib was overall well-tolerated and demonstrated a favorable safety profile, supporting chronic use in this patient population. Most adverse events related to treatment were mild to moderate in severity.
COGT’s Next Steps in the Bezuclastinib Development Program
Based on the encouraging data readout, Cogent Biosciences is gearing up to submit its first new drug application to the FDA, seeking the approval of bezuclastinib for non-advanced SM, by the end of 2025. Subject to approval, management believes that the candidate has the potential to become a new standard of care for this patient population, where there is a significant unmet medical need.
A comprehensive analysis of the full SUMMIT Part 2 data is currently underway and COGT intends to present the detailed findings at a major medical conference later this year.
Apart from the non-advanced SM indication, Cogent Biosciences is simultaneously evaluating bezuclastinib for advanced SM and gastrointestinal stromal tumors in separate pivotal late-stage studies, APEX and PEAK, respectively. Top-line data from both phase III studies are anticipated in the second half of 2025.
Cogent Biosciences, Inc. Price and Consensus
Cogent Biosciences, Inc. price-consensus-chart | Cogent Biosciences, Inc. Quote
COGT’s Zacks Rank and Stocks to Consider
Cogent Biosciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) , Verona Pharma (VRNA - Free Report) and Bayer (BAYRY - Free Report) . While IMCR and VRNA sport a Zacks Rank #1 (Strong Buy) each, BAYRY carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, loss per share estimates for Immunocore’s 2025 have improved from $1.44 to 70 cents. Loss per share estimates for 2026 have narrowed from $1.45 to $1.08 during the same period. IMCR stock has gained 9.9% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
In the past 90 days, Verona Pharma’s bottom-line estimates for 2025 have significantly improved from a loss of 7 cents per share to earnings of 22 cents. During the same timeframe, estimates for 2026 earnings per share have improved from $2.21 to $2.88. VRNA stock has soared 96.4% so far this year.
Verona Pharma’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, delivering an average negative surprise of 6.76%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.27 for 2025 over the past 90 days, while that for 2026 has gone up from $1.28 to $1.34 over the same timeframe. Year to date, shares of Bayer have surged 56.6%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.